Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR), a clinical-stage biopharmaceutical company focused on developing oral small molecule therapeutics for metabolic and cardiopulmonary diseases, has announced its participation in the Jefferies London Healthcare Conference. The event will take place from November 19-21, 2024, in London, UK.
The company's management will deliver a presentation and participate in a fireside chat on Wednesday, November 20 at 8:00 a.m. GMT, while also hosting one-on-one meetings. A live webcast will be available on the company's website, with a replay accessible for 90 days following the event.
Details
News Market Reaction – GPCR
The recorded move for GPCR in the trading session of this news was -9.34%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that management will participate in a presentation and fireside chat, and host one-on-one meetings at the Jefferies London Healthcare Conference being held November 19-21, 2024, in London, UK.
Jefferies London Healthcare Conference
| Format: | Presentation and fireside chat | |
| Date/time: | Wednesday, November 20 at 8:00 a.m. GMT | |
The live and archived webcast will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and a replay will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more patients around the world. For additional information, please visit www.structuretx.com.
Investors:
Danielle Keatley
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.